China-based global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) announced on Wednesday that it has named Xu Wang as its new chief executive officer (CEO).
Wang succeeds Dave Chenn and Dr Hui Shao, who has stepped down from the company's interim CEO and co-CEO positions, respectively.
Wang has worked as the firm's chief operation officer since June 2024, and will no longer assume such role upon becoming the company's chief executive officer.
Valneva licenses Shigella vaccine candidate from LimmaTech
myTomorrows names new director
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
Latigo Biotherapeutics names new chief executive officer
Valneva receives CEPI funding to boost access to world's first chikungunya vaccine
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
INOVIO names new chief commercial officer
Dynavax Technologies commences dosing in Z-1018 phase 1/2 clinical trial
Bavarian Nordic files for chikungunya vaccine approval in Europe
Valneva's chikungunya vaccine IXCHIQ approved by Health Canada
Philippine lawmakers call for probe into secret US propaganda operation